NPI: 1730184342 · SHEBOYGAN, WI 53081 · General Acute Care Hospital · NPI assigned 06/20/2005
Authorized official ALLEN, PATRICIA controls 18+ related entities in our dataset. Read more
| Authorized Official | ALLEN, PATRICIA (CFO) |
| NPI Enumeration Date | 06/20/2005 |
Other providers sharing the same authorized official: ALLEN, PATRICIA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 31,083 | $571K |
| 2019 | 32,535 | $600K |
| 2020 | 29,665 | $549K |
| 2021 | 41,602 | $696K |
| 2022 | 46,819 | $902K |
| 2023 | 44,434 | $928K |
| 2024 | 30,422 | $792K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,197 | 10,570 | $692K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5,471 | 4,146 | $602K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 10,433 | 8,748 | $478K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1,380 | 1,200 | $324K |
| 41899 | Unlisted procedure, dentoalveolar structures | 776 | 665 | $319K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4,215 | 3,061 | $248K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5,811 | 4,925 | $240K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3,787 | 3,350 | $220K |
| 80053 | Comprehensive metabolic panel | 10,757 | 8,767 | $196K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2,794 | 2,454 | $165K |
| 70450 | Computed tomography, head or brain; without contrast material | 2,546 | 2,233 | $131K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1,555 | 1,343 | $116K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 596 | 537 | $105K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 16,282 | 12,556 | $96K |
| 80048 | Basic metabolic panel (calcium, ionized) | 6,056 | 4,840 | $81K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,633 | 1,328 | $70K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,750 | 1,421 | $64K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2,394 | 1,202 | $61K |
| G0378 | Hospital observation service, per hour | 1,095 | 848 | $52K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1,460 | 1,079 | $44K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 472 | 333 | $40K |
| 84484 | 5,153 | 3,324 | $40K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,451 | 1,268 | $40K |
| 80306 | 1,618 | 1,371 | $39K | |
| 81025 | 4,213 | 3,606 | $38K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,567 | 736 | $37K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 600 | 519 | $37K |
| 87486 | 1,381 | 1,201 | $35K | |
| 81001 | 8,720 | 7,345 | $34K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 470 | 416 | $32K |
| 87581 | 1,378 | 1,198 | $31K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 142 | 125 | $27K |
| 83605 | 2,932 | 2,109 | $19K | |
| 83690 | 3,823 | 3,219 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,876 | 1,635 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 206 | 188 | $18K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 620 | 559 | $17K |
| 71046 | Radiologic examination, chest; 2 views | 2,643 | 2,377 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | 1,055 | 946 | $14K |
| 80076 | 2,229 | 1,927 | $13K | |
| 83880 | 602 | 538 | $11K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 112 | 95 | $10K |
| 72125 | Computed tomography, cervical spine; without contrast material | 538 | 483 | $10K |
| 83735 | 2,578 | 2,003 | $9K | |
| 85379 | 1,245 | 1,114 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 396 | 363 | $8K |
| 87040 | 1,610 | 779 | $8K | |
| 82805 | 374 | 288 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 181 | 174 | $7K |
| 85610 | 2,215 | 1,754 | $7K | |
| 86140 | 1,437 | 1,211 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 181 | 175 | $6K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 370 | 328 | $6K |
| 87081 | 302 | 272 | $5K | |
| 94664 | 215 | 181 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 98 | 91 | $5K |
| 87077 | 588 | 461 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7,696 | 6,113 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 383 | 341 | $4K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 103 | 49 | $4K |
| 85730 | 932 | 799 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 29 | 13 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 8,302 | 6,531 | $2K |
| 87186 | 451 | 353 | $2K | |
| 85652 | 918 | 786 | $2K | |
| 80061 | Lipid panel | 79 | 75 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | 6,878 | 5,222 | $2K |
| 71045 | Radiologic examination, chest; single view | 3,875 | 3,253 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3,115 | 2,285 | $2K |
| 86850 | 72 | 61 | $1K | |
| 97597 | 80 | 44 | $1K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 109 | 85 | $1K |
| 84439 | 133 | 119 | $1K | |
| 93971 | 41 | 40 | $1K | |
| 85027 | 97 | 79 | $944.34 | |
| 84702 | 57 | 49 | $709.52 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 12 | 12 | $694.82 |
| G0379 | Direct admission of patient for hospital observation care | 14 | 12 | $654.09 |
| 83036 | Hemoglobin; glycosylated (A1C) | 55 | 50 | $629.37 |
| 82565 | 53 | 44 | $591.40 | |
| 87807 | 43 | 40 | $472.57 | |
| 94060 | 30 | 27 | $335.04 | |
| 86901 | 118 | 102 | $241.21 | |
| 86900 | 118 | 102 | $241.21 | |
| 94729 | 86 | 78 | $240.59 | |
| 87088 | 42 | 37 | $239.95 | |
| 87210 | 42 | 40 | $175.56 | |
| 94726 | 27 | 24 | $152.17 | |
| 36415 | Collection of venous blood by venipuncture | 2,114 | 1,658 | $117.29 |
| 87070 | 18 | 12 | $71.02 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,652 | 1,613 | $69.13 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 5,938 | 4,749 | $53.02 |
| 81003 | 48 | 31 | $45.03 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 32 | 25 | $42.22 |
| 87205 | 18 | 12 | $35.55 | |
| 73630 | 76 | 69 | $34.60 | |
| 96376 | 2,055 | 1,501 | $23.59 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 1,370 | 1,028 | $22.86 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5,644 | 4,371 | $21.24 |
| J7030 | Infusion, normal saline solution , 1000 cc | 7,345 | 5,740 | $20.76 |
| J3490 | Unclassified drugs | 3,480 | 1,947 | $13.37 |
| C9113 | Injection, pantoprazole sodium, per vial | 34 | 26 | $12.45 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 6,005 | 4,773 | $7.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 3,824 | 2,795 | $5.99 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 100 | 88 | $5.53 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 5,853 | 3,693 | $5.10 |
| 73030 | 14 | 13 | $4.47 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 4,161 | 3,258 | $3.16 |
| J0690 | Injection, cefazolin sodium, 500 mg | 762 | 607 | $2.60 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 55 | 52 | $2.05 |
| J2704 | Injection, propofol, 10 mg | 3,575 | 2,373 | $1.30 |
| J1170 | Injection, hydromorphone, up to 4 mg | 2,408 | 1,739 | $0.74 |
| 88304 | 16 | 12 | $0.47 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3,156 | 2,456 | $0.09 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 935 | 695 | $0.01 |
| A9270 | Non-covered item or service | 1,753 | 1,215 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 241 | 181 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 858 | 629 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 1,170 | 957 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 41 | 24 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 1,041 | 854 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 542 | 420 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 220 | 151 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 44 | 40 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 121 | 96 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 70 | 58 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 13 | 12 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 1,067 | 758 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 2,309 | 1,849 | $0.00 |
| 88312 | 255 | 204 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1,869 | 1,602 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 37 | 15 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 49 | 39 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 229 | 188 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 130 | 111 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 61 | 40 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 34 | 28 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 48 | 44 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 29 | 12 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 32 | 27 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 23 | 18 | $0.00 |
| 73610 | 17 | 14 | $0.00 |